Skip to content

Access BNP Clinical Enrollment Study

Access BNP Assay Clinical Subject Sample Collection Enrollment Study Protocol

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06624293
Enrollment
1100
Registered
2024-10-02
Start date
2024-08-30
Completion date
2025-02-18
Last updated
2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The goal of this study is to collect blood from subjects with a suspicion of either new onset or worsened heart failure to be used for testing studies for a new product to aid in the diagnosis of heart failure.

Interventions

DIAGNOSTIC_TESTBNP

Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.

Sponsors

Beckman Coulter, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to provide informed consent * Adult greater than or equal to 22 years old, any gender, race, ethnicity * Presenting with clinical suspicion of new onset heart failure or worsening symptoms suggestive of decompensated or exacerbated heart failure * Ability to fulfill study data collection requirements (including responding to questions for the NYHA evaluation)

Exclusion criteria

* Individuals less than 22 years old * Impairment in individual's capacity to give informed consent * Dyspnea clearly not secondary to heart failure (e.g., primary lung disease or chest trauma). * On dialysis * On nesiritide infusion * Subject clinical/medical history access is not available to Sponsor, delegates, and FDA or other regulatory agencies upon request. * Active participation in a clinical study that may interfere with participation in this study (e.g., investigational drug study) * Reason(s) determined by the Principal Investigator that would place the individual at increased risk or preclude the individual from fully complying with or completing the study.

Design outcomes

Primary

MeasureTime frameDescription
Heart failure positive subjectsDuring initial assessment in emergency departmentSubjects with BNP value above clinical decision point

Secondary

MeasureTime frameDescription
Heart failure negative subjectsDuring initial assessment in emergency departmentSubjects with BNP value below clinical decision point

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026